Icon Genetics GmbH

Halle (Saale), Germany

Icon Genetics GmbH

Halle (Saale), Germany
SEARCH FILTERS
Time filter
Source Type

Patent
Icon Genetics GmbH | Date: 2017-04-26

System for producing a nucleic acid construct of interest, said system comprising:a set of n destination vectors (destination vectors M), n being an integer of at least 2, preferably at least 3,each of said n destination vectors M comprising in the following order:(I) a type IIs restriction endonuclease recognition site defining the cleavage site of item (II);(II) the cleavage site of said recognition site of item (I);(III) a cleavage site of said recognition site of the following item (IV);(IV) a further type IIs restriction endonuclease recognition site defining the cleavage site of item (III) and being a different recognition site of a type IIs restriction endonuclease from that of item (I);(V) a vector backbone comprising a selectable marker gene, said vector backbone linking the cleavage sites of said recognition sites of item and (IV) and the following item (VI);(VI) a further type IIs restriction endonuclease cleavage site;(VII) a type IIs restriction endonuclease recognition site of the cleavage site of item (VI) and(VIII) optionally, an insert between the recognition sites of item (VII) and item (I); anda set of n linkers M, n being as defined above, each linker M comprising in the following order:(a) a type IIs restriction endonuclease recognition site defining the cleavage site of item (b);(b) the cleavage site of said recognition site of item (a);(c) a cleavage site of a further type IIs restriction endonuclease recognition site of item (d), said cleavage site having the same sequence of nucleotides as the cleavage site of item (b);(d) the type IIs restriction endonuclease recognition site defining the cleavage site of item (c) and being a different recognition site of a type IIs restriction endonuclease different from that of item (a);(e) a further cleavage site of a type IIs restriction endonuclease recognition site of the following item (f);(f) the type IIs restriction endonuclease recognition site defining the cleavage site of item (e), that is preferably a recognition site of the same endonuclease as the recognition site of item (a).


Patent
Bayer Innovation Gmbh, Icon Genetics GmbH and CureVac GmbH | Date: 2013-01-30

The present invention is directed to a pharmaceutical composition including (eg for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components and as a cargo at least one nucleic acid (molecule) and at least one antigen associated with a tumour or cancer disease selected from; an idiotype immunoglobulin (e.g. an idiotype antibody or an idiotype B cell receptor); or at least one idiotype T cell receptor, or in each case a fragment, variant and/or derivative thereof. The inventive pharmaceutical composition allows for efficient induction of an adaptive immune response directed against the idiotype immunoglobulin or T cell receptor, particularly of a Th1-shiftet immune response. The present invention furthermore provides kits or kits of parts comprising the components of the inventive pharmaceutical composition, as well as the use of the inventive pharmaceutical composition or the inventive kit as a vaccine, particularly in the therapy of a tumour or cancer disease such as lymphoma, particularly B cell or T cell lymphoma.


Patent
Icon Genetics GmbH and Mapp Biopharmaceutical, Inc. | Date: 2012-09-27

Disclosed herein are GNGN and G1/G2 antibodies that recognize and bind various FcRs and C1q. Also disclosed herein are glycan-optiminzed antibodies, predominantly of the GNGN or G1/G2 glycoform, with enhanced Fc receptor binding achieved through CHO, Nicotiana benthamiana and yeast manufacturing systems. Nucleic acids encoding these antibodies, as well as expression vectors and host cells including these nucleic acids are also disclosed herein. Methods and pharmaceutical compositions including the monoclonal antibodies are provided herein for the prevention and/or therapeutic treatment of viral infections, cancers and inflammatory diseases.


Patent
Icon Genetics GmbH | Date: 2012-07-27

The invention provides methods for increasing the levels of bi-antennary mono- and fully galactosylated N-glycans, and for decreasing the levels of hybrid-type galactosylated N-glycans on glycoproteins produced in plants or plant cells. In addition, the invention provides methods for the production of heterologous glycoproteins with increased levels of bi-antennary mono- and fully galactosylated N-glycans, or decreased levels of hybrid-type galactosylated N-glycans in plants or plant cells.


Patent
Icon Genetics GmbH | Date: 2013-01-30

The invention provides methods for increasing the levels of bi-antennary mono- and fully galactosylated N-glycans, and for decreasing the levels of hybrid-type galactosylated N-glycans on glycoproteins produced in plants or plant cells. In addition, the invention provides methods for the production of heterologous glycoproteins with increased levels of bi-antennary mono- and fully galactosylated N-glycans, or decreased levels of hybrid-type galactosylated N-glycans in plants or plant cells.


Patent
Icon Genetics GmbH | Date: 2016-01-05

A process of expressing a sequence of interest in a plant, plant part, or plant cell culture, comprising: (a) providing a plant, plant part, or plant cell culture containing in cell nuclei a heterologous DNA having a sequence encoding an RNA replicon operably linked or linkable to a transcription promoter, wherein said sequence encoding an RNA replicon contains (i) sequences for replicon function of said RNA replicon, said sequences being derived from a sequence of a plant RNA virus, (ii) a sequence of interest, whereby said sequences for replicon function exhibit at selected localities of said sequences of said plant RNA virus function-conservative differences from said sequence of said plant RNA virus, said differences causing an increased frequency of replicon formation compared to an RNA replicon not exhibiting said differences; and (b) causing expression of said sequence of interest.


Patent
Icon Genetics GmbH | Date: 2014-11-24

Process of producing in a plant, in plant tissue, or in plant cells a hetero-oligomeric protein comprising at least a first and a second protein subunit, said process comprising expressing in plant cells at least said first and said second protein subunit by


Patent
Icon Genetics GmbH | Date: 2014-09-17

Protein conjugate comprising a protein antigen and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen(i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or(ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or(iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.


A process of producing a recombinant glycoprotein in a plant, in cells of a plant, or in plant cells, comprising expressing in said plant, in cells of said plant or in said plant cells a nucleic acid sequence encoding a polypeptide, said polypeptide having an N-glycosylation site of consensus sequence Asn-X-Ser or Asn-X-Thr, X being any standard amino acid residue, wherein, if the Asn residue of said N-glycosylation site is assigned amino acid sequence position 0,


Patent
Icon Genetics GmbH and University of Southampton | Date: 2014-03-11

Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen

Loading Icon Genetics GmbH collaborators
Loading Icon Genetics GmbH collaborators